Search
Editas Medicine Inc
EDITAdd to Watchlist
3.650USD
+0.370+11.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
340.42MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+11.28%
5 Days
+28.07%
1 Month
+22.07%
6 Months
+78.05%
Year to Date
+78.05%
1 Year
+42.02%
Key Figures
3.330Open
3.680High
4.20MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
4.51%Turnover Ratio
3.280Prev. Close
3.317Low
10.25MTurnover
LossP/E Static
25.30P/B
0.00%Div Yield TTM
-52.76%ROA
4.53752wk High
1.92Volume Ratio
-237.09MNet Profit
93.26MShares
-1.1427EPS TTM
2.16Beta
-326.07%ROE
1.66052wk Low
11.08%Amplitude
100.00%Gross Margin
340.42MMarket Cap
1.74Reward/Risk
5.57%Risk Rate
TradingKey Stock Score of Editas Medicine Inc
Currency: USD Updated: 2026-07-02Key Insights
Editas Medicine Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 126 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.66.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Editas Medicine Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Editas Medicine Inc Highlights
StrengthsRisks
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Growing
The company is in a growing phase, with the latest annual income totaling USD 40.52M.
Undervalued
The company’s latest PE is -3.19, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.01M shares, decreasing 24.99% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 45.76K shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
5.660
Target Price
+72.56%
Upside Space
Editas Medicine Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Editas Medicine Inc Info
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Ticker SymbolEDIT
CompanyEditas Medicine Inc
CEOO'Neill (Gilmore Neil)
Websitehttps://www.editasmedicine.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Editas Medicine Inc (EDIT)?
The current price of Editas Medicine Inc (EDIT) is 3.65.
What is the symbol of Editas Medicine Inc?
The ticker symbol of Editas Medicine Inc is EDIT.
What is the 52-week high of Editas Medicine Inc?
The 52-week high of Editas Medicine Inc is 4.54.
What is the 52-week low of Editas Medicine Inc?
The 52-week low of Editas Medicine Inc is 1.66.
What is the market capitalization of Editas Medicine Inc?
The market capitalization of Editas Medicine Inc is 340.42M.
Is Editas Medicine Inc (EDIT) currently rated as Buy, Hold, or Sell?
According to analysts, Editas Medicine Inc (EDIT) has an overall rating of Buy, with a price target of 5.66.
What is the Earnings Per Share (EPS TTM) of Editas Medicine Inc (EDIT)?
The Earnings Per Share (EPS TTM) of Editas Medicine Inc (EDIT) is -1.80.